These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7702069)

  • 1. Proceedings from improving patient outcomes with higher hematocrit levels. Satellite symposium of the American Society of Nephrology 27th annual meeting. Orlando, Florida, October 26, 1994.
    Am J Kidney Dis; 1995 Apr; 25(4 Suppl 1):S1-17. PubMed ID: 7702069
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in nephrology: highlights from the 35th annual meeting of the American society of nephrology.
    Cases A
    Drugs Today (Barc); 2002 Dec; 38(12):797-805. PubMed ID: 12582469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings of the American Society of Therapeutic Radiologists' 24th annual meeting. October 25-29, 1982, Orlando, Florida. Abstracts.
    Int J Radiat Oncol Biol Phys; 1982 Oct; 8 Suppl 1():1-148. PubMed ID: 7153108
    [No Abstract]   [Full Text] [Related]  

  • 5. Proceedings of the American Society for Therapeutic Radiology and Oncology, 27th annual meeting. September 29-October 4, 1985, Miami Beach, Florida. Abstracts.
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11 Suppl 1():1-222. PubMed ID: 4019283
    [No Abstract]   [Full Text] [Related]  

  • 6. Trends in anemia at initiation of dialysis in the United States.
    Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
    Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Nephrology. 27th annual meeting. October 26-29, 1994. Abstracts.
    J Am Soc Nephrol; 1994 Sep; 5(3):245-1045. PubMed ID: 7948789
    [No Abstract]   [Full Text] [Related]  

  • 8. Good response of endogenous erythropoietin to blood loss in persistently improving renal anemia after discontinuation of erythropoietin treatment.
    Yabana M; Ikeda Y; Kihara M; Kurita K; Toya Y; Tamura K; Takagi N; Onishi T; Umemura S
    Nephron; 1999 Jan; 81(1):111-2. PubMed ID: 9884433
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
    Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
    Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The latest advances in kidney diseases and related disorders.
    Cases A
    Drug News Perspect; 2007 May; 20(4):271-8. PubMed ID: 17637941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erythropoietin treatment in Piedmont and Valle d'Aosta].
    Imarisio P; Biamino E; Bongiorno P; Caligaris F; Demicheli G; Montalcini G; Arnaud A
    Minerva Urol Nefrol; 1991; 43(3):143-5. PubMed ID: 1817336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy.
    Movilli E; Pertica N; Camerini C; Cancarini GC; Brunori G; Scolari F; Maiorca R
    Am J Kidney Dis; 2002 Apr; 39(4):850-3. PubMed ID: 11920353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should the hematocrit be normalized in dialysis and in pre-ESRD patients?
    Macdougall IC
    Blood Purif; 2001; 19(2):157-67. PubMed ID: 11150803
    [No Abstract]   [Full Text] [Related]  

  • 14. Opportunities to improve the care of patients with kidney transplant failure.
    Gill JS; Abichandani R; Khan S; Kausz AT; Pereira BJ
    Kidney Int; 2002 Jun; 61(6):2193-200. PubMed ID: 12028460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In search of an optimal hematocrit level in dialysis patients: rehabilitation and quality-of-life implications.
    Paganini EP
    Am J Kidney Dis; 1994 Jul; 24(1 Suppl 1):S10-6; discussion S31-2. PubMed ID: 8023833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What is the right hematocrit in patients with chronic renal failure?].
    Deray G
    Presse Med; 1999 Feb; 28(5):234-5. PubMed ID: 10076601
    [No Abstract]   [Full Text] [Related]  

  • 17. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 18. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes!
    Besarab A; Aslam M
    Blood Purif; 2001; 19(2):168-74. PubMed ID: 11150804
    [No Abstract]   [Full Text] [Related]  

  • 20. Is erythropoietin effective for impotence in dialysis patients?
    Imagawa A; Kawanishi Y; Numata A
    Nephron; 1990; 54(1):95-6. PubMed ID: 2296352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.